Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489191 | 0.91 | TSHR (0.73) | TSHRHPGDMEN1KMT2ASLC6A5 | |
| SCHEMBL16190625 | 0.89 | TSHR (0.65) | TSHRHPGDMEN1KMT2ASLC6A5 | |
| SCHEMBL14262301 | 0.89 | TSHR (0.81) | TSHRHPGDMEN1KMT2AKDM4E | |
| SCHEMBL22418053 | 0.88 | TSHR (0.68) | TSHRHPGDMEN1KMT2ASLC6A5 | |
| SCHEMBL26742630 | 0.86 | TSHR (0.59) | TSHRHPGDMEN1KMT2ASLC6A5 | |
| SCHEMBL1709113 | 0.85 | TSHR (0.63) | TSHRHPGDMEN1KMT2ASLC6A5 | |
| SCHEMBL12013653 | 0.85 | TSHR (0.88) | TSHRHPGDMEN1KMT2AKDM4E | |
| SCHEMBL4270085 | 0.85 | TSHR (0.88) | TSHRHPGDMEN1KMT2AKDM4E | |
| SCHEMBL8574782 | 0.85 | TSHR (0.88) | TSHRHPGDMEN1KMT2AKDM4E | |
| SCHEMBL12013650 | 0.85 | TSHR (0.88) | TSHRHPGDMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4194553-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| WO-2021254360-A1 | CARBOHYDRATE MOLECULAR CLUSTER AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | ACOT7, COASY, LCAT | TSHR 1805/4885HPGD 3373/4885MEN1 1068/4885 |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | TSHR 1805/4885HPGD 3373/4885MEN1 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.